<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83915">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01820949</url>
  </required_header>
  <id_info>
    <org_study_id>380/12</org_study_id>
    <nct_id>NCT01820949</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients</brief_title>
  <acronym>PBM</acronym>
  <official_title>Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius Kabi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospitals</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate clinical outcome after the step-wise implementation of a Patient
      Blood Management (PBM) Program in surgical patients at 4 hospitals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A PBM program will be implemented stepwise in four University Hospitals, with the intention
      to optimize preoperative hemoglobin concentration of patients and to standardize transfusion
      practice within hemotherapy. The PBM program includes 1) an algorithm with the aim to
      correct preoperative anemia in elective surgery, 2) a strict indication for the transfusion
      of red blood cells defined by the &quot;Cross-sectional Guidelines for Therapy with Blood
      Components and Plasma Derivatives&quot; for all surgical patients, and 3) a perioperative
      checklist for different blood-sparing techniques (e.g. cell-saver, normothermia, reduced
      blood samples, point-of-care diagnostics for bedside coagulation management).

      Primary endpoint: Safety of the use of PBM program will be determined by comparability of
      the composite outcome (in-hospital myocardial infarction, stroke, acute renal failure, death
      of any cause, pneumonia and sepsis until discharge from hospital) between patients treated
      after implementation and patients treated before implementation (control cohort) of the PBM
      program.

      The primary composite endpoint defined as described above will be registered electronically
      by analysis of Diagnosis Related Groups (DRG) codes. The frequency of these events will be
      compared between PBM and control cohort stratified by center with a one-sided
      Mantel-Haenszel test in a non-inferiority setting with significance level of α=2.5% and a
      non-inferiority margin of 1% for the incidence of the composite endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsisComposite outcome</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Composite endpoint defined as in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay on the intensive care unit</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of red blood cell transfusions during hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of coagulation factors, crystalloid and colloid infusions</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80000</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Control cohort</arm_group_label>
    <description>Standard care before implementation (pre-implementation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBM cohort</arm_group_label>
    <description>After implementation of PBM program (post-implementation)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all surgical patients over a period of 24 months at 4 hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All non- ambulant, surgical, anesthetized patients (≥18 years)

          -  General Surgery, Cardiac Surgery, Thoracic Surgery, Trauma Surgery, Vascular Surgery,
             Urology, Gynecology, Otolaryngology, Neurosurgery, Crania-Maxillofacial Surgery

        Exclusion Criteria:

          -  ambulant and all non-surgical anesthetic procedures

          -  Surgery in the field of Dermatology or Ophthalmology
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Zacharowski, MD, PhD, FRCA</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Meybohm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erhard Seifried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Red Cross Blood Service Baden-Württemberg-Hessen, Institute for Transfusion Medicine and Immunohematology of the Goethe University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva Herrmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Biostatistics and Mathematical Modeling, Goethe University Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Meybohm, MD</last_name>
    <email>patrick.meybohm@kgu.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Wittmann, MD</last_name>
      <email>Maria.Wittmann@ukb.uni-bonn.de</email>
    </contact>
    <contact_backup>
      <last_name>Georg Baumgarten</last_name>
    </contact_backup>
    <investigator>
      <last_name>Georg Baumgarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Wittmann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Hoeft, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Meybohm, MD</last_name>
      <email>patrick.meybohm@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Kai Zacharowski, MD, PhD, FRCA</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kai Zacharowski, MD, PhD, FRCA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Meybohm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Müller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Geisen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erhard Seifried, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dania Fischer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Zeuzem, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Nussbaumer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Renner, MD</last_name>
      <email>jochen.renner@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Berthold Bein, MD</last_name>
      <email>berthold.bein@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jochen Renner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berthold Bein, MD, MA, DESA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Scholz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Zarbock, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Zarbock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 26, 2013</lastchanged_date>
  <firstreceived_date>March 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Professor Kai Zacharowski, M.D., Ph.D., FRCA</investigator_full_name>
    <investigator_title>Prof. Dr. Dr. Kai Zacharowski</investigator_title>
  </responsible_party>
  <keyword>patient blood management</keyword>
  <keyword>patients safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
